Similar articles

• [Sarcoidosis after interferon-alpha treatment in hepatitis C].

  Krehmeier H, Egberts EH. Krehmeier H, et al. Dtsch Med Wochenschr. 2001 Apr 20;126(16):460. doi: 10.1055/s-2001-12892. Dtsch Med Wochenschr. 2001. PMID: 11360451 German. No abstract available.
• A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.

  Uyama H, Enomoto H, Kishima Y, Yamamoto M, Yoshida K, Okuda Y, Hirotani T, Kuroda T, Ito H, Matsuda M, Terabayashi M, Noguchi S, Kawase I, Nakamura H. Uyama H, et al. Hepatogastroenterology. 2003 Nov-Dec;50(54):2112-6. Hepatogastroenterology. 2003. PMID: 14696476 Clinical Trial.
• Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C.

  Nomura H, Miyagi Y, Tanimoto H, Yamashita N. Nomura H, et al. J Infect Chemother. 2014 Aug;20(8):489-92. doi: 10.1016/j.jiac.2014.04.009. Epub 2014 May 22. J Infect Chemother. 2014. PMID: 24857619
• [Antiviral therapy for chronic viral hepatitis B and C].

  Iino S. Iino S. Nihon Rinsho. 2003 Feb;61 Suppl 2:787-91. Nihon Rinsho. 2003. PMID: 12722317 Review. Japanese. No abstract available.
• Is {beta}-interferon a promising therapeutic option for the management of hepatitis C?

  Hosseini-Moghaddam SM, Mousavi A, Alavian SM. Hosseini-Moghaddam SM, et al. J Antimicrob Chemother. 2009 Jun;63(6):1097-103. doi: 10.1093/jac/dkp092. Epub 2009 Mar 27. J Antimicrob Chemother. 2009. PMID: 19329508 Review.